Effect of a pyrimidine derivative on the level of cytokines in conditions of streptococcal wound infection

Diseases caused by Streptococcus pyogenes are one of the significant problems of practical health care, due to the ability of this pathogen to cause morbidity in all age groups of the population with the development of different complications. The streptococcal infection is accompanied, along with infectious and inflammatory symptoms, by a pronounced immune response to Streptococcus pyogenes, which is mediated by the functional activity of monocytes and dendritic cells responsible for the production of pro- and anti-inflammatory cytokines that regulate the interaction, proliferation and functional activity of all participants in the cellular and humoral links of immunity. The purpose is to study the effect of a pyrimidine derivative on the level of pro- (IL-1β, IL-6, IL-8) and anti-inflammatory interleukins (IL-4, IL-10) in conditions of experimental streptococcal wound infection. The study of the effect of the pyrimidine derivative 3-[2-[(4,6-dimethylpyrimidin-2-yl) amino]-2-oxoethyl]quinazolin-4(3H)-one was carried out in vivo on the model streptococcal wound infection. The experiments were carried out on CBA mice 3 months old (20-22 g). Animals were divided into groups: control I–healthy animals, which were injected with water for injection; control II–infected untreated animals; experience I – animals that were treated intraperitoneally with a pyrimidine derivative at a dose of 36 mg/kg for 7 days, starting from the first day of infection; experiment II – animals that were treated intraperitoneally with the reference drug cefepime at an average therapeutic dose of 50 mg/kg in the same regimen as the test compound. The levels of pro- and anti-inflammatory interleukins in blood serum were determined by enzyme immunoassay. The study found that the pyrimidine derivative 3-[2-[(4,6-dimethylpyrimidin-2-yl)amino]-2-oxoethyl]quinazolin-4(3H)-one under conditions of streptococcal wound infection has an immunoregulatory effect, manifested in a decrease in pro-inflammatory and an increase in anti-inflammatory interleukins.

1. Burova L.A., Suvorov A.N., Totolyan A.A. Streptococcus pyogenes: the phenomenon of non-immune binding of human immunoglobulins and its role in pathology. Meditsinskaya immunologiya = Medical Immunology (Russia), 2022, Vol. 24, no. 2, pp. 217-234. (In Russ.) doi: 10.15789/1563-0625-SPP-2450.

2. Burova L.A., Totolyan A.A. The main pathogenicity factors of Streptococcus pyogenes. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2022, Vol. 12, no. 1, pp. 33-50. (In Russ.) doi: 10.15789/2220-7619-MPF-1723.

3. Kovalenko L.P., Nikitin S.V., Kuznetsova O.S., Zhurikov R.V., Sorokina A.V., Miroshkina I.A., Korzhova K.V. Study of antiinflammatory, immunomodulatory and antitumor properties of SNK-411. Eksperimentalnaya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology, 2018, Vol. 81, no. S, P. 115. (In Russ.)

4. Krasnitskaya A.S., Bocharova O.S., Pervov Yu.Yu., Klimkina T.N. Characteristics of the local cytokine profile in patients with chronic tonsillitis depending on the etiology. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2019, Vol. 22, no. 2-1, pp. 338-340. (In Russ.) doi: 10.31857/S102872210006620-7.

5. Nurboev H.I. Pyrimidine derivatives and their use in medicine. Boshqaruv va etika qoidalari onlayn ilmiy jurnali = Online Journal of Management and Ethics, 2022, Vol. 2, no. 4, pp. 32-35. (In Russ.)

6. Freidlin I.S., Starikova E.A., Lebedeva A.M. Overcoming the protective functions of macrophages by virulence factors of Streptococcus pyogenes. Byulleten sibirskoy meditsiny = Bulletin of Siberian Medicine, 2019, Vol. 18, no 1, pp. 109-118. (In Russ.)

7. Tsibizova A.A., Tyurenkov I.N., Ozerov A.A., Bashkina O.A., Samotrueva M.A. Regulatory effect of a quinazoline derivative with an alpha-naphthyl radical on the level of TNFα, IL-6, and IL-10 under conditions of experimental generalized infection. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal, 2020, Vol. 15, no. 4, pp. 97-107. (In Russ.)

8. Tsibizova A.A., Yasenyavskaya A.L., Ozerov A.A., Samotrueva M.A., Tyurenkov I.N. Evaluation of the acute toxicity of a new pyrimidine derivative. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal, 2021, Vol. 16, no. 1, pp. 82-87. (In Russ.)

9. Chiryapkin A.S. Review of pyrimidine derivatives as pharmacologically active compounds. Juvenis Scientia = Juvenis Scientia, 2022, Vol. 8, no 5, pp. 16-30. (In Russ.)

10. Anderson D., Imran S., Frost H.R., Azzopardi K.I., Jalali S., Novakovich B., Pellicci D.G. The immune signature of acute pharyngitis in the study of Streptococcus pyogenes in humans. Nat. Commun., 2022, Vol. 13, no. 1, 769. doi: 10.1038/s41467-022-28335-3.

11. Avire N.J., While H., Ross K. Review of Streptococcus pyogenes: public health risk factors, prevention and control. Pathogens, 2021, Vol. 10, no. 2, 248. doi: 10.3390/pathogens10020248.

12. Gonzales A.J., Bowman J.W., Fici G.J., Zhang M., Mann D.W., Mitton-Fry M. Oclacitinib (APOQUEL(®)) is a novel janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther., 2014, Vol. 37, no. 4, pp. 317-324.

13. Morelli M., Scarponi C., Mercurio L., Facchiano F., Pallotta S., Madonna S., Girolomoni G., Albanesi C. Selective immunomodulation of inflammatory pathways in keratinocytes by the janus kinase(JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis. J. Immunol. Res., 2018, Vol. 2018, 7897263. doi: 10.1155/2018/7897263.

14. Rath E., Palma Medina L.M., Jahagirdar S., Mosevoll K.A., Damås J.K., Madsen M.B., Svensson M., Hyldegaard O., Martins Dos Santos V.A.P.; INFECT Study group; Saccenti E., Norrby-Teglund A., Skrede S., Bruun T. Systemic immune activation profiles in streptococcal necrotizing soft tissue infections: A prospective multicenter study. Clin. Immunol., 2023, Vol. 249, no. 9, 109276. doi: 10.1016/j.clim.2023.109276.

15. Singh S.B., Young K., Silver L.L. What is an “ideal” antibiotic? Challenges of discovery and the way forward. Biochem. Pharmacol., 2017, no. 133, pp. 63-73.

16. Yılmaz Ç., Özcengiz G. Antibiotics: Pharmacokinetics, toxicity, resistance and multi-drug efflux pumps. Biochem. Pharmacol., 2017, no. 133, pp. 43-62.